Cipher Pharmaceuticals (TSE:CPH) Stock Price Down 18.7% – Should You Sell?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares fell 18.7% on Wednesday . The company traded as low as C$13.96 and last traded at C$14.60. 235,912 shares changed hands during trading, an increase of 768% from the average session volume of 27,167 shares. The stock had previously closed at C$17.95.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group set a C$17.00 price objective on shares of Cipher Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, Cipher Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of C$17.00.

Cipher Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.32, a current ratio of 1.25 and a quick ratio of 2.67. The business’s 50-day moving average price is C$16.68 and its two-hundred day moving average price is C$16.61. The firm has a market cap of C$370.20 million, a price-to-earnings ratio of 12.25 and a beta of 1.15.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings data on Tuesday, August 11th. The company reported C$0.21 EPS for the quarter. The firm had revenue of C$17.14 million for the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. On average, research analysts forecast that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.